Last reviewed · How we verify

NCT04628962: CORSAI

Raman Analysis of Saliva as Biomarker of COPD

Status unknown Last updated 4 April 2022
What this trial tests

trial testing Collection and Raman analysis of saliva for the database in Chronic Obstructive Pulmonary Disease in 250 participants. Status unknown.

Timeline
1 February 2022
Primary endpoint
30 November 2023
1 January 2025

Quick facts

Lead sponsorFondazione Don Carlo Gnocchi Onlus
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment250
Start date1 February 2022
Primary completion30 November 2023
Estimated completion1 January 2025
Sites5 locations across Italy, Germany, Spain, Latvia

Drugs / interventions tested

Conditions studied

Sponsor

Fondazione Don Carlo Gnocchi Onlus — full company profile →

Who can join

18 and older, any sex, with Chronic Obstructive Pulmonary Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chronic Obstructive Pulmonary Disease (COPD) is a debilitating and chronic lung syndrome that causes accelerated lung function decline and death in the 20% of cases. Mostly, the non-adherence to therapy contributes to symptoms increase, mortality, inability and therapies failure, highly influencing the management costs associated to COPD. The existing procedure of diagnosing COPD is effective and fast. The acute treatment and the subsequent disease management, instead, strictly depend on the currently long and complex process of identification of three factors: COPD phenotype, adherence to chosen therapy and probability of exacerbation events. The knowledge of these factors is needed by clinicians to stratify patients and personalise the therapies and rehabilitation procedures, to initiate an effective disease management. The application of Raman spectroscopy on saliva, representing an easy collectable and highly informative biofluid, has been already proposed for different infective, neurological and cancer diseases, with promising results in the diagnostic and monitoring fields. In this project, we propose the use of Deep Learning analysis of Raman spectra collected from COPD patient's saliva to be combined with other clinical data for the development of a system able to provide fast and sensitive information regarding COPD phenotypes, adherence and exacerbation risks. This will support clinicians to personalise COPD therapies and treatments, and to monitor their effectiveness.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Perspective of Future SERS Clinical Application Based on Current Status of Raman Spectroscopy Clinical Trials.
    Xi X, Liang C. · · 2021 · cited 14× · PMID 34354978 · DOI 10.3389/fchem.2021.665841
  2. Characterization of the COPD Salivary Fingerprint through Surface Enhanced Raman Spectroscopy: A Pilot Study.
    Carlomagno C, Gualerzi A, Picciolini S, Rodà F, et al · · 2021 · cited 5× · PMID 33809282 · DOI 10.3390/diagnostics11030508
  3. Development of a Raman-Based Method for the Diagnosis of People with Obstructive Sleep Apnea Syndrome: The Role of Lactic Acid.
    Forleo L, Picciolini S, Gualerzi A, Battaglia E, et al · · 2025 · PMID 41009657 · DOI 10.3390/ijms26189095

Verify or expand the search:

Other recruiting trials for Chronic Obstructive Pulmonary Disease

Currently open trials in the same condition.

Other Fondazione Don Carlo Gnocchi Onlus trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04628962.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing